Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

TIPRANKS00:00

Austin, Texas, United States, August 17th, 2026, FinanceWire Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, wit...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660393394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660393394","market":"fut","top_or_hot":-1,"title":"Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks","media":"TIPRANKS","content":"<div>\n<p>Austin, Texas, United States, August 17th, 2026, FinanceWire Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, wit...</p>\n\n<a href=\"https://www.tipranks.com/news/newswire/regentis-biomaterials-nyse-american-rgnt-moves-gelrinc-along-parallel-us-clinical-and-european-commercial-tracks?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-18 00:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/newswire/regentis-biomaterials-nyse-american-rgnt-moves-gelrinc-along-parallel-us-clinical-and-european-commercial-tracks?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Austin, Texas, United States, August 17th, 2026, FinanceWire Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, wit...</p>\n\n<a href=\"https://www.tipranks.com/news/newswire/regentis-biomaterials-nyse-american-rgnt-moves-gelrinc-along-parallel-us-clinical-and-european-commercial-tracks?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGNT","symbol_name":"Regentis Biomaterials Ltd.","start_time":0,"source_url":"https://www.tipranks.com/news/newswire/regentis-biomaterials-nyse-american-rgnt-moves-gelrinc-along-parallel-us-clinical-and-european-commercial-tracks?utm_source=itigerup.com&utm_medium=referral","article_id":"2660393394","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/regentis-biomaterials-nyse-american-rgnt-moves-gelrinc-along-parallel-us-clinical-and-european-commercial-tracks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660393394","pubTimestamp":1786982415,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Austin, Texas, United States, August 17th, 2026, FinanceWire Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, wit...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RGNT":"Regentis Biomaterials Ltd.","AFG":"美国金融集团有限公司","BK4107":"财产与意外伤害保险","EPV":"ProShares UltraShort MSCI Europe","BK4117":"多元化保险","BK4139":"生物科技","NYSE":"纽交所"},"translate_title":"Regentis Biomaterials（纽约证券交易所美国股票代码：RGNT）推动 GelrinC 沿着平行的美国临床和欧洲商业轨道发展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPV":1.5,"NYSE":1.5,"AFG":1.5,"RGNT":1.5},"content_text":"Austin, Texas, United States, August 17th, 2026, FinanceWire Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, wit...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660393394","isCrawlerRequest":true}